

# Clinical trials of Drug eluting stent for coronary artery disease in diabetic patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 drug-eluting stents

Trial	Treatments	Patients	Trials design and methods
<b>paclitaxel eluting stent vs bare-metal stent</b>			
<b>TAXUS II (diabetics) , 2003</b> <i>unpublished</i> n=37/41 follow-up: 12 months	TAXUS versus NIR stent	Diabetic patients with stable or unstable AP, silent ischaemia; single de novo target lesion with estimated stenosis >50% and <99% ,	Parallel groups double-blind Europe
<b>TAXUS IV (diabetics) , 2005</b> [NCT00292474] n=155/163 follow-up: 9 months	TAXUS versus EXPRESS	Diabetic patients with stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm)	Parallel groups double-blind United States
<b>TAXUS V (diabetics) , 2005</b> n=178/171 follow-up: 9 months	TAXUS versus BMS	Diabetic patients with stable or unstable AP, silent ischaemia with complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents)	Parallel groups double-blind United States
<b>TAXUS VI (diabetics) , 2005</b> [NCT00297804] n=39/50 follow-up: 9 months	TAXUS versus Express2 stent	Diabetic patients with stable or unstable AP, silent ischaemia with long, complex coronary artery lesions	Parallel groups double-blind Europe
<b>sirolimus eluting stent vs bare-metal stent</b>			
<b>DECODE , 2005</b> <i>unpublished</i> [NCT00489164] n=54/29 follow-up: 1 year	CYPHER (Up to 3 stents per patient were allowed) versus Bx VELOCITY (Up to 3 stents per patient were allowed)	Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels	Parallel groups open US, Asia/Pacific
<b>DESSERT , 2008</b> n=75/75 follow-up: 12 months	Cypher and Cypher Select versus Sonic (Cordis)	de novo lesions of diabetic patients treated with insulin and/or oral antidiabetics for >3 months	Parallel groups single-blind Italy
<b>DIABETES , 2005</b> n=80/80 follow-up: 9 months	Cypher versus Bx Velocity/Sonic	de novo lesions in native coronary arteries in 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm	Parallel groups open Spanish
<b>Ravel (diabetics) , 2004</b> n=19/25 follow-up: 6 months	coated Bx velocity versus Bx VELOCITY	sub groups of diabetic patients with de novo native coronary artery lesions 2.5 to 3.5 mm in diameter by visual assessment that could be covered by an 18-mm stent	Parallel groups NA Europe

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>SES-SMART (diabetics) , 2005</b> n=29/45 follow-up: 8 months	Cypher versus Bx Sonic	Diabetic patients with de novo target lesion <=2.75 mm in diameter in a native coronary artery that could be completely covered by a single stent (maximum length 33 mm)	Parallel groups single-blind Italy
<b>SIRIUS (diabetics) , 2003</b> n=131/148 follow-up: 12 months	SES versus BMS	sub group of diabetics patients of SIRIUS study	Parallel groups double-blind US
<b>CoStar stent vs paclitaxel eluting stent</b>			
<b>COSTAR II diabetic (sub group) , 2008</b> n=271/271 follow-up: 8 months	CoStar stent (PES) versus Taxus stent (PES)	patients with de novo single- or multivessel coronary disease	Parallel groups open
<b>paclitaxel eluting balloon vs paclitaxel eluting stent</b>			
<b>PEPCAD IV <i>ongoing</i></b> [NCT00462631] n=NA follow-up:	Paclitaxel-eluting PTCA-balloon dilation (SeQuent™ Please) followed by cobalt-chromium stent (Coroflex™ Blue) deployment versus Taxus Libert	patients with diabetes mellitus	open
<b>sirolimus eluting stent vs paclitaxel eluting stent</b>			
<b>DES-DIABETES , 2008</b> n=200/200 follow-up: 9 months (1 year)	sirolimus-eluting stent versus paclitaxel-elutingstent	diabetic patients with angina pectoris and/or a positive stress test and a native coronary lesion	Factorial plan open Korea
<b>ISAR-DIABETES , 2005</b> n=125/125 follow-up: 9 months	Taxus versus Cypher	Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel	Parallel groups open Germany
<b>Kim , 2008</b> n=85/84 follow-up: 6 months	Cypher versus Taxus	Korean diabetic patients with high-grade de novo coronary lesions (stenosis of >70 percent of the luminal diameter) requiring <3 stents	Parallel groups open Korea
<b>REALITY (diabetics) , 2006</b> <i>unpublished</i> n=187/192 follow-up: 12 months	SES versus PES	-	Parallel groups open worldwide
<b>SIRTAX diabetics , 2005</b> [NCT00297661] n=108/93 follow-up: 12 months	Cypher versus Taxus	Sub groups of diabetics patients with either stable angina or an acute coronary syndrome	Parallel groups single-blind Switzerland
<b>TAXI (diabetics) , 3000</b> <i>unpublished</i> n=33/36 follow-up: 12 months	SES versus PES	-	Parallel groups open Switzerland

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>Tomai , 2008</b> n=60/60 follow-up: 8 months	sirolimus-eluting stent versus paclitaxel-eluting stent	diabetic patient with multiple de novo coronary artery lesions	Cross over NA Italy
<b>Lipsia-Yukon-DM ongoing</b> [NCT00368953] n=NA follow-up: 9 months	Yukon Choice stent system versus Taxus Libert stent system	Patients With Diabetes Mellitus	
<b>paclitaxel eluting stent vs sirolimus eluting stent</b>			
<b>ISAR-test (diabetics) , 2006</b> n=73/58 follow-up: 9 months	Taxus versus rapamycin stent	diabetics patients with de novo lesions in native coronary vessels, excluding the left main trunk	Parallel groups open germany
<b>zotarolimus eluting stent vs sirolimus eluting stent</b>			
<b>DIABEDES IV ongoing</b> [NCT00552994] n=NA follow-up:	Cypher select plus versus Xience V	diabetic patients	

## References

### **TAXUS II (diabetics), 2003:**

Hermiller J. Diabetic results: Taxus II, IV and VI TCT [0]

### **TAXUS IV (diabetics), 2005:**

Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-9 [15837245]

### **TAXUS V (diabetics), 2005:**

Ellis SG TAXUS V trial global results: expanding the randomizeddata 2005 American College of CardiologyAnnual Scientific Session

### **TAXUS VI (diabetics), 2005:**

Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13 [16286586]

### **DECODE, 2005:**

Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M. Outcomesin diabetic patients with multivessel disease and long lesions: resultsfrom the DECODE study Am J Cardiol 2005; 96 (suppl 7A): 31H

### **DESSERT, 2008:**

Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L, Sangiorgio P, Zoccai GB Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 2008;101:1560-6 [18489933]

### **DIABETES, 2005:**

Sabat M, Jimnez-Quevedo P, Angiolillo DJ, Gmez-Hospital JA, Alfonso F, Hernndez-Antoln R, Goicolea J, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83 [16203930]

Jimnez-Quevedo P, Sabat M, Angiolillo DJ, Alfonso F, Hernndez-Antoln R, SanMartn M, Gmez-Hospital JA, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya C Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007;28:1946-52 [[17562666](#)]

**Ravel (diabetics), 2004:**

**SES-SMART (diabetics), 2005:**

**SIRIUS (diabetics), 2003:**

**COSTAR II diabetic (sub group), 2008:**

**PEPCAD IV, 0:**

**DES-DIABETES, 2008:**

**ISAR-DIABETES, 2005:**

**Kim, 2008:**

**REALITY (diabetics), 2006:**

**SIRTAX diabetics, 2005:**

**TAXi (diabetics), 3000:**

**Tomai, 2008:**

**Lipsia-Yukon-DM, 0:**

**ISAR-test (diabetics), 2006:**

**DIABEDES IV, 0:**

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.